# HLA-B27: Ankylosing Spondylitis Risk Allele, Heavy Chain Misfolding, and Arthritogenic Peptide Presentation


## Key Takeaways

- HLA-B*27 is a major risk allele for ankylosing spondylitis (AS), conferring an odds ratio exceeding 50, and its pathogenic mechanisms are multifactorial, involving arthritogenic peptide presentation, heavy chain misfolding leading to unfolded protein response (UPR), and cell-surface homodimer formation.
- The HLA-B heavy chain, particularly the B*27:05 subtype, exhibits a propensity for misfolding in the endoplasmic reticulum, triggering the UPR and subsequent pro-inflammatory cytokine production (IL-23, IL-17) via IRE1α and PERK pathways, contributing to AS pathogenesis.
- Cell-surface homodimers of HLA-B27 heavy chains, facilitated by Cys67, engage innate immune receptors like KIR3DL2 on CD4+ T cells, promoting IL-17 secretion, and LILRB2 on myeloid cells, amplifying inflammation.
- Specific HLA-B alleles, such as HLA-B*57:01 and HLA-B*15:02, are critical pharmacogenomic biomarkers, dictating contraindications or screening recommendations for drugs like abacavir and carbamazepine, respectively, due to severe hypersensitivity reactions.
- HLA-B plays a dual role in viral immunity, presenting viral peptides to CD8+ T cells for control (e.g., HIV-1 control by B*57 and B*27), while also being a target for viral immune evasion strategies, such as downregulation by HIV-1 Nef and HCMV US proteins.

---

## Executive Summary & Key Metadata

The human leukocyte antigen (HLA) class I heavy chain encoded by the **HLA-B** gene is among the most polymorphic loci in the human genome, with over 7,000 known alleles cataloged in the IPD-IMGT/HLA database. The gene product is a 362-amino-acid transmembrane glycoprotein that non-covalently associates with β2-microglobulin (β2m) and a short peptide (8–10 residues) to form the peptide-loading complex (PLC). This ternary complex is the molecular scaffold for CD8+ T-cell surveillance of intracellular proteomes. The allele **HLA-B*27** is uniquely associated with the seronegative spondyloarthropathies, most notably ankylosing spondylitis (AS), conferring an odds ratio of >50 in HLA-B27-positive individuals. The pathogenic mechanism is multifactorial, involving (i) the presentation of arthritogenic peptides to CD8+ T cells, (ii) heavy chain misfolding leading to the unfolded protein response (UPR), and (iii) the formation of cell-surface homodimers that engage innate immune receptors such as KIR3DL2 and LILRB2.

| Attribute | Value |
|-----------|-------|
| **HGNC Symbol** | HLA-B |
| **UniProt Accession** | P01889 |
| **Representative PDB ID** | 1HOC (HLA-B*27:05 complexed with a nonameric viral peptide) |
| **Chromosomal Locus** | 6p21.33 (MHC class I region) |
| **Primary Molecular Function** | Peptide antigen presentation to CD8+ T cells; modulation of NK cell activity via KIR engagement |
| **Disease & Pathology Associations** | Ankylosing spondylitis (AS), reactive arthritis (ReA), acute anterior uveitis (AAU), psoriatic arthritis (PsA), inflammatory bowel disease (IBD)-associated spondyloarthritis; HIV-1 control (HLA-B*57); drug hypersensitivity (HLA-B*15:02 with carbamazepine) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Coordinates

The HLA-B gene resides within the **major histocompatibility complex (MHC)** on the short arm of chromosome 6, specifically at **6p21.33** (GRCh38/hg38: chr6:31,353,872–31,357,207; minus strand). The MHC spans approximately 3.6 Mb and is subdivided into three regions: class I (telomeric), class III (central), and class II (centromeric). HLA-B is positioned within the class I region, flanked by HLA-C (centromeric) and the MICA/MICB genes (telomeric). The genomic organization is notable for its high gene density and extreme [linkage disequilibrium](/knowledge/bioinformatics/linkage-disequilibrium-and-haplotype-mapping) (LD), which extends across the entire MHC. The LD structure has profound implications for disease association studies, as the causal variant may be in strong LD with HLA-B itself.

### 1.2 Promoter Architecture and Transcriptional Regulation

The HLA-B promoter is a **TATA-less, initiator (Inr)-containing promoter** that relies on a proximal **SXY module**—a composite regulatory element composed of the S, X1, X2, and Y boxes. This module is the binding site for the **RFX complex** (RFX5, RFXAP, RFXANK), **CIITA** (class II transactivator), and **NF-Y** (nuclear transcription factor Y). Although CIITA is classically associated with MHC class II genes, it also regulates class I genes, including HLA-B, via the SXY module. The X2 box binds **ATF1/CREB** and **X2BP**, while the Y box binds NF-Y. The S box is recognized by RFX. This promoter architecture ensures coordinated upregulation of HLA-B in response to **interferon-γ (IFN-γ)** and **tumor necrosis factor-α (TNF-α)**.

Enhancer elements upstream of the promoter include an **enhancer A (enhA)** region containing **κB sites** that bind NF-κB (p50/p65 heterodimers) and an **ISRE (interferon-stimulated response element)** that binds IRF1 and IRF2. The combination of enhA and ISRE confers robust inducibility by type I and type II interferons. A **negative regulatory element (NRE)** located between enhA and the SXY module binds the transcriptional repressor **ZNF165** and the chromatin remodeler **CHD4**, providing basal repression in non-immune tissues.

### 1.3 Alternative Splicing and Isoform Diversity

The HLA-B gene comprises **8 exons**:

- **Exon 1**: 5' untranslated region (UTR) and signal peptide (leader sequence)
- **Exon 2**: α1 domain (residues 1–90)
- **Exon 3**: α2 domain (residues 91–182)
- **Exon 4**: α3 domain (residues 183–274)
- **Exon 5**: Transmembrane domain
- **Exon 6**: Cytoplasmic tail (short)
- **Exon 7**: Cytoplasmic tail (alternative)
- **Exon 8**: 3' UTR

Alternative splicing generates several minor isoforms. The most functionally relevant is a **soluble HLA-B (sHLA-B)** isoform produced by intron 4 retention, which introduces a premature stop codon and results in a truncated protein lacking the transmembrane and cytoplasmic domains. sHLA-B is secreted into plasma and can modulate immune responses by inducing apoptosis in activated CD8+ T cells via Fas/FasL interactions. A second isoform, **HLA-B-Δ5**, skips exon 5, producing a glycosylphosphatidylinositol (GPI)-anchored form. The functional significance of GPI-anchored HLA-B is not fully resolved, but it may participate in antigen cross-presentation.

### 1.4 Allelic Diversity and Haplotype Structure

The HLA-B locus is the most polymorphic in the human genome. As of 2026, the IPD-IMGT/HLA database lists over **7,500 alleles** encoding more than **5,000 distinct proteins**. The polymorphism is concentrated in the **peptide-binding groove** (α1 and α2 domains), specifically in residues that line the B and F pockets. This diversity is maintained by **balancing selection**, likely driven by the need to present a broad repertoire of pathogen-derived peptides. The most studied alleles include:

- **HLA-B*27:05** (associated with AS; most common B27 subtype in Caucasians)
- **HLA-B*27:04** (AS-associated in Asians)
- **HLA-B*57:01** (associated with HIV-1 control and abacavir hypersensitivity)
- **HLA-B*15:02** (associated with carbamazepine-induced Stevens-Johnson syndrome)
- **HLA-B*35:01** (associated with rapid progression to AIDS)

The **HLA-B*27:05** allele is distinguished by a free cysteine at position 67 (Cys67) in the α1 domain, which is critical for homodimer formation via disulfide bonding. The B*27:06 and B*27:09 subtypes, which are not associated with AS, differ at positions 114 and 116 (Asp116→His in B*27:09), altering the F pocket specificity and reducing the arthritogenic peptide repertoire.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Boundaries and Topology

The mature HLA-B heavy chain (after cleavage of the 24-residue signal peptide) is a **362-amino-acid type I transmembrane glycoprotein** with the following domain architecture:

- **α1 domain (residues 1–90)**: Forms the N-terminal half of the peptide-binding groove. Contains the B pocket (residues 7, 9, 24, 34, 45, 63, 66, 67, 70, 99) and part of the A pocket.
- **α2 domain (residues 91–182)**: Forms the C-terminal half of the groove. Contains the F pocket (residues 77, 80, 81, 84, 95, 97, 99, 114, 116, 123, 133, 143, 146, 147, 155, 159, 160, 171).
- **α3 domain (residues 183–274)**: Immunoglobulin-like constant domain. Contains the binding site for CD8 (loop residues 223–229) and β2m.
- **Transmembrane domain (residues 275–311)**: Hydrophobic α-helix anchoring the protein in the plasma membrane.
- **Cytoplasmic tail (residues 312–362)**: Contains phosphorylation sites (Ser335, Ser339) and a PDZ-binding motif (residues 360–362: SLL) that interacts with PDZ domain-containing scaffolds.

### 2.2 Peptide-Binding Groove Architecture

The peptide-binding groove is formed by the α1 and α2 domains, each contributing a long α-helix and a β-pleated sheet. The groove is approximately **25 Å long, 10 Å wide, and 8 Å deep**, accommodating peptides of 8–10 residues in an extended conformation. The peptide is anchored at its N-terminus (P1) in the A pocket and at its C-terminus (PΩ) in the F pocket. The B pocket accommodates the P2 anchor residue, which for HLA-B*27 is **Arg** (positively charged), coordinated by Glu45, Glu63, Cys67, and His9. The F pocket accommodates the C-terminal anchor, which for B*27 is typically a hydrophobic residue (Leu, Ile, Val, or Tyr), coordinated by Asp77, Thr80, Leu81, and Asp116.

The **B*27:05** subtype has a preference for peptides with Arg at P2 and a hydrophobic or aromatic residue at PΩ. This motif is shared by self-peptides derived from cytosolic proteins (e.g., vasoactive intestinal peptide receptor, ribosomal proteins) and viral peptides (e.g., influenza nucleoprotein). The **arthritogenic peptide hypothesis** posits that B*27 presents a specific self-peptide (or set of peptides) that triggers an autoreactive CD8+ T-cell response, leading to joint inflammation. Candidate arthritogenic peptides include those derived from **collagen type II**, **proteoglycan**, and **heat shock protein 60 (Hsp60)**.

### 2.3 Structural Features of B*27:05: Cys67 and Homodimer Formation

A unique structural feature of B*27:05 is the presence of **Cys67** in the α1 helix. This residue is solvent-exposed and can form intermolecular disulfide bonds with another B*27 heavy chain, leading to the formation of **β2m-free homodimers (HC-B27)**. These homodimers are expressed on the cell surface of activated T cells, B cells, and monocytes. The crystal structure of HC-B27 (PDB: 3BP7) reveals that the homodimer is formed by domain swapping of the α1 domains, creating a novel "open" conformation that is recognized by **KIR3DL2** (killer cell immunoglobulin-like receptor) on NK cells and a subset of CD4+ T cells. Engagement of KIR3DL2 by HC-B27 triggers pro-inflammatory cytokine production (IL-17, IFN-γ) and inhibits NK cell cytotoxicity, contributing to the chronic inflammation characteristic of AS.

### 2.4 β2-Microglobulin Interaction and Stability

The heavy chain associates non-covalently with **β2-microglobulin (β2m)**, a 99-residue immunoglobulin-like protein encoded on chromosome 15. The interaction interface involves the α1, α2, and α3 domains, with the α3 domain contributing the majority of contact residues. The binding of β2m is essential for the structural stability of the peptide-receptive conformation. In the absence of β2m, the heavy chain is thermodynamically unstable and prone to misfolding. The **peptide-loading complex (PLC)** in the endoplasmic reticulum (ER) ensures that only stable, peptide-loaded trimers are exported to the cell surface. The PLC comprises **TAP1/TAP2** (transporter associated with antigen processing), **tapasin**, **calreticulin**, **ERp57**, and **calnexin**. Tapasin edits the peptide repertoire, favoring high-affinity peptides that confer kinetic stability to the trimer.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load HLA-B (PDB: 1HOC)](/tools/protein-structure-viewer?source=direct&pdbId=1HOC)

The PDB entry **1HOC** is a high-resolution (2.1 Å) crystal structure of HLA-B*27:05 complexed with a nonameric peptide (sequence: RRYQKSTEL) derived from the influenza A nucleoprotein. The structure reveals the canonical MHC class I fold, with the peptide deeply buried in the groove. Key structural features to visualize:

- **α1 and α2 helices** forming the groove walls
- **β-sheet floor** of the groove
- **P2 Arg** of the peptide buried in the B pocket
- **Cys67** on the α1 helix (solvent-exposed)
- **α3 domain** and its interaction with β2m

### 2.6 Post-Translational Modifications

HLA-B undergoes several co- and post-translational modifications:

- **N-linked glycosylation** at Asn86 (α1 domain): The glycan is processed in the ER and Golgi, and the mature complex glycan is important for intracellular trafficking and cell-surface stability.
- **Disulfide bond** between Cys101 and Cys164 in the α2 domain: This intradomain disulfide is essential for the structural integrity of the α2 domain.
- **Phosphorylation** of Ser335 and Ser339 in the cytoplasmic tail: Phosphorylation by protein kinase C (PKC) modulates the interaction with PDZ domain-containing proteins and influences receptor internalization.
- **Palmitoylation** of Cys321 and Cys337: This modification anchors the cytoplasmic tail to the inner leaflet of the plasma membrane, affecting lateral mobility and clustering.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Antigen Processing and Presentation Pathway

The primary function of HLA-B is to present endogenous peptides to CD8+ T cells. The pathway begins with the **proteasome**, which degrades ubiquitinated cytosolic proteins into peptides of 8–16 residues. The immunoproteasome (induced by IFN-γ) contains the catalytic subunits β1i (LMP2), β2i (MECL-1), and β5i (LMP7), which generate peptides with a preference for hydrophobic C-terminal residues—optimal for MHC class I binding. Peptides are translocated into the ER by **TAP1/TAP2**, a heterodimeric ATP-binding cassette (ABC) transporter. In the ER, the PLC facilitates peptide loading onto the HLA-B heavy chain-β2m heterodimer. Tapasin stabilizes the empty heterodimer and edits the peptide repertoire, favoring peptides with high affinity and slow dissociation kinetics. The peptide-loaded trimer is then transported via the **secretory pathway** to the cell surface, where it is recognized by the T-cell receptor (TCR) on CD8+ T cells.

### 3.2 CD8+ T-Cell Activation and Co-Stimulation

The engagement of the peptide-HLA-B complex by a cognate TCR triggers a signaling cascade in the CD8+ T cell. The CD8 co-receptor binds to the α3 domain of HLA-B, stabilizing the TCR-peptide-MHC interaction and recruiting the Src kinase **Lck** to the TCR complex. Lck phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3ζ chains, leading to the recruitment and activation of **ZAP-70**. ZAP-70 phosphorylates the adaptor proteins **LAT** and **SLP-76**, initiating downstream signaling cascades that culminate in the activation of **NFAT**, **NF-κB**, and **AP-1** transcription factors. This results in the production of IL-2, IFN-γ, and TNF-α, and the proliferation and differentiation of the T cell into a cytotoxic effector cell.

### 3.3 NK Cell Regulation via KIR and LILR Engagement

HLA-B also serves as a ligand for **killer cell immunoglobulin-like receptors (KIRs)** and **leukocyte immunoglobulin-like receptors (LILRs)** expressed on NK cells and subsets of T cells. The interaction between HLA-B and inhibitory KIRs (e.g., KIR3DL1) delivers a negative signal that prevents NK cell-mediated lysis of healthy cells. The specificity of this interaction is determined by the **Bw4/Bw6 epitope** in the α1 domain (residues 77–83). HLA-B alleles with the Bw4 motif (e.g., B*27, B*57) are recognized by KIR3DL1, while Bw6 alleles (e.g., B*08, B*35) are not. The Bw4/KIR3DL1 interaction is associated with improved control of HIV-1 and other viral infections.

In the context of AS, the **HC-B27 homodimers** engage **KIR3DL2** (an activating receptor) and **LILRB2** (an inhibitory receptor). The engagement of KIR3DL2 on CD4+ T cells triggers the production of IL-17, a key cytokine in the pathogenesis of AS. The engagement of LILRB2 on dendritic cells and macrophages promotes the secretion of pro-inflammatory cytokines (IL-1β, TNF-α) and inhibits apoptosis.

### 3.4 Unfolded Protein Response (UPR) and ER Stress

The **heavy chain misfolding hypothesis** proposes that B*27 has an intrinsic propensity to misfold in the ER, particularly when β2m is limiting. The misfolded heavy chain accumulates in the ER, triggering the **unfolded protein response (UPR)**. The UPR is mediated by three ER-resident sensors: **IRE1α**, **PERK**, and **ATF6**. Activation of IRE1α leads to the splicing of XBP1 mRNA, producing a potent transcription factor that upregulates ER chaperones and ER-associated degradation (ERAD) components. Activation of PERK phosphorylates eIF2α, attenuating global protein synthesis while selectively upregulating ATF4, which drives the expression of pro-apoptotic genes (CHOP). Activation of ATF6 releases a cytosolic fragment that translocates to the nucleus and upregulates chaperone genes.

In B*27-expressing cells, the UPR is chronically activated, leading to the production of **IL-23** and **IL-17** by macrophages and T cells, respectively. IL-23 is a key cytokine in the differentiation and maintenance of Th17 cells, which are central to the inflammatory response in AS. The UPR also activates the **NLRP3 inflammasome**, leading to the cleavage of pro-IL-1β into its active form and the secretion of IL-1β, further amplifying inflammation.

### 3.5 Autophagy and Cross-Presentation

B*27 heavy chains that misfold in the ER can be retrotranslocated to the cytosol and degraded by the proteasome. However, a fraction of these misfolded heavy chains are targeted to **autophagosomes** and delivered to lysosomes for degradation. The autophagic pathway intersects with the MHC class II presentation pathway, allowing B*27-derived peptides to be presented to CD4+ T cells. This may contribute to the loss of immune tolerance and the activation of autoreactive CD4+ T cells in AS.

### 3.6 Protein-Protein Interaction Networks

The HLA-B protein interacts with a large network of proteins involved in antigen processing, trafficking, and signaling. Key interactors (from BioGRID and STRING) include:

- **TAP1/TAP2**: Peptide transport
- **Tapasin (TAPBP)**: Peptide editing
- **Calreticulin (CALR)**: Chaperone
- **ERp57 (PDIA3)**: Disulfide isomerase
- **β2-microglobulin (B2M)**: Light chain
- **CD8A**: Co-receptor
- **KIR3DL1**: NK cell receptor
- **KIR3DL2**: NK cell receptor (binds HC-B27)
- **LILRB2**: Inhibitory receptor
- **PDZ domain-containing proteins** (e.g., DLG1, MPP1): Scaffolding

```mermaid
sequenceDiagram
    participant Proteasome
    participant TAP
    participant ER
    participant PLC
    participant HLA-B
    participant Golgi
    participant CellSurface
    participant TCR/CD8
    participant NK/KIR

    Proteasome->>TAP: Peptides (8-16 aa)
    TAP->>ER: Peptide translocation
    ER->>PLC: Peptide loading onto HLA-B/β2m
    PLC->>HLA-B: Stable trimer formation
    HLA-B->>Golgi: Trafficking
    Golgi->>CellSurface: Expression
    CellSurface->>TCR/CD8: Antigen presentation
    TCR/CD8-->>HLA-B: Activation signal
    CellSurface->>NK/KIR: Bw4/KIR3DL1 interaction
    NK/KIR-->>HLA-B: Inhibitory signal
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The B27 Subtype Spectrum and AS Risk

The association between HLA-B27 and AS is one of the strongest known HLA-disease associations. However, not all B27 subtypes confer equal risk. The following subtypes are associated with AS:

- **B*27:05**: Strongly associated (OR > 50 in Caucasians)
- **B*27:04**: Strongly associated (in Asians)
- **B*27:02**: Moderately associated
- **B*27:07**: Weakly associated

The following subtypes are **not** associated with AS:

- **B*27:06**: Differs from B*27:05 at positions 114 (Asp→His) and 116 (Asp→Tyr)
- **B*27:09**: Differs from B*27:05 at position 116 (Asp→His)

The structural basis for the differential risk lies in the **F pocket**. In B*27:05, Asp116 forms a salt bridge with the C-terminal anchor residue of the peptide. In B*27:09, the substitution of Asp116 with His alters the electrostatic environment of the F pocket, changing the peptide repertoire. The B*27:09 subtype presents a more restricted set of peptides, which may lack the specific arthritogenic peptide(s) that trigger the autoimmune response.

### 4.2 Cys67 and Homodimer Formation

The **Cys67** residue is unique to B*27 subtypes and is essential for the formation of HC-B27 homodimers. Substitution of Cys67 with Ser (as in B*27:03) or Tyr (as in B*27:06) abrogates homodimer formation. The loss of homodimer formation is correlated with reduced AS risk, supporting the hypothesis that HC-B27 homodimers contribute to pathogenesis via KIR3DL2 engagement.

### 4.3 ClinVar Pathogenic Variants

ClinVar lists several pathogenic variants in HLA-B, primarily associated with drug hypersensitivity and immune-mediated diseases:

| Variant | Allele | Clinical Significance | Associated Phenotype |
|---------|--------|----------------------|----------------------|
| p.Asp116His | B*27:09 | Protective | Reduced AS risk |
| p.Asp116Tyr | B*27:06 | Protective | Reduced AS risk |
| p.Cys67Ser | B*27:03 | Risk modifier | Reduced homodimer formation |
| p.Ile80Thr | B*15:02 | Pathogenic | Carbamazepine-induced SJS/TEN |
| p.Ser116Tyr | B*57:01 | Pathogenic | Abacavir hypersensitivity |
| p.Asn97Ser | B*35:01 | Risk | Rapid HIV-1 progression |

### 4.4 HLA-B*57:01 and Abacavir Hypersensitivity

HLA-B*57:01 is strongly associated with **abacavir hypersensitivity syndrome** (ABC-HSR), a potentially fatal adverse drug reaction. The mechanism involves the non-covalent binding of abacavir to the F pocket of HLA-B*57:01, altering the peptide repertoire and triggering an autoimmune-like T-cell response. The presence of the B*57:01 allele is a mandatory screening test before abacavir prescription. The structural basis for this interaction was elucidated by X-ray crystallography, revealing that abacavir occupies the F pocket and changes the conformation of the peptide-binding groove.

### 4.5 HLA-B*15:02 and Carbamazepine-Induced SJS/TEN

HLA-B*15:02 is strongly associated with **carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)** in Han Chinese and other Asian populations. The mechanism is similar to abacavir hypersensitivity: carbamazepine binds to the peptide-binding groove, altering the presented peptide repertoire and activating CD8+ T cells. Screening for HLA-B*15:02 is recommended before carbamazepine use in at-risk populations.

### 4.6 HLA-B and HIV-1 Control

HLA-B*57 and HLA-B*27 are associated with **elite control of HIV-1**—the ability to maintain undetectable viral loads without antiretroviral therapy. The mechanism involves the presentation of highly conserved HIV-1 Gag epitopes (e.g., KK10 for B*27, TW10 for B*57) that elicit robust CD8+ T-cell responses. [Viral escape mutations](/knowledge/bioinformatics/predicting-viral-escape-mutations-computational-structural-analysis-antibody-binding-interfaces) in these epitopes often incur a fitness cost, limiting viral replication. The B*57/TW10 interaction is characterized by a unique peptide conformation that is recognized by a public TCR clonotype.

### 4.7 Differential Diagnosis in Clinical Immunology

The presence of HLA-B27 is used as a diagnostic marker for AS and related spondyloarthropathies. However, the positive predictive value is low in populations with low disease prevalence. HLA-B27 testing is most useful in patients with inflammatory back pain and radiographic evidence of sacroiliitis. The differential diagnosis includes:

- **Ankylosing spondylitis**: Bilateral sacroiliitis, syndesmophytes, bamboo spine
- **Reactive arthritis (Reiter's syndrome)**: Asymmetric oligoarthritis, urethritis, conjunctivitis
- **Psoriatic arthritis**: Psoriasis, nail pitting, dactylitis
- **IBD-associated spondyloarthritis**: Crohn's disease or ulcerative colitis with axial involvement
- **Acute anterior uveitis**: Unilateral, recurrent, HLA-B27-associated

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Immune Evasion via HLA-B Downregulation

Many viruses have evolved mechanisms to downregulate HLA-B expression to evade CD8+ T-cell recognition. The **human cytomegalovirus (HCMV)** encodes several proteins that interfere with MHC class I antigen presentation:

- **US2 and US11**: Retrotranslocate HLA-B heavy chains from the ER to the cytosol for proteasomal degradation
- **US3**: Retains MHC class I molecules in the ER
- **US6**: Inhibits TAP-mediated peptide translocation
- **US8**: Binds to MHC class I molecules and prevents their recognition by NK cells

The **HIV-1 Nef** protein downregulates HLA-B and [HLA-A](/knowledge/bioinformatics/genes/immunology-checkpoints/hla-a-gene-structure-function-pathway) (but not HLA-C) from the cell surface by promoting their internalization and degradation in lysosomes. This selective downregulation preserves the inhibition of NK cells via HLA-C and HLA-E, while evading CD8+ T-cell responses. The **Vpu** protein of HIV-1 also downregulates HLA-B, albeit to a lesser extent than Nef.

### 5.2 Viral Peptide Presentation and CTL Responses

HLA-B presents a wide array of viral peptides to CD8+ T cells. Notable examples include:

- **Influenza A nucleoprotein** (residues 383–391: SRYWAIRTR) presented by B*27:05
- **HIV-1 Gag** (residues 263–272: KRWIILGLNK, KK10) presented by B*27:05
- **HIV-1 Gag** (residues 240–249: TSTLQEQIGW, TW10) presented by B*57:01
- **Epstein-Barr virus (EBV) EBNA3C** (residues 258–266: RRIYDLIEL) presented by B*27:05
- **Hepatitis C virus (HCV) NS3** (residues 1359–1367: HSKKKCDEL) presented by B*27:05

The presentation of these peptides is associated with effective viral control. For example, the B*27-restricted KK10 epitope in HIV-1 Gag is associated with slow disease progression, and viral escape mutations in this epitope are associated with a loss of immune control.

### 5.3 Bacterial Superantigens and HLA-B

Certain bacterial superantigens (e.g., staphylococcal enterotoxins) can cross-link MHC class II molecules with TCRs, leading to massive T-cell activation. While HLA-B is not a primary target for superantigens, the **Yersinia enterocolitica** and **Salmonella** species—which trigger reactive arthritis in HLA-B27-positive individuals—may produce peptides that are presented by B*27 and activate autoreactive T cells. The molecular mimicry hypothesis suggests that bacterial peptides share sequence or structural homology with self-peptides, leading to cross-reactive T-cell responses.

### 5.4 The Role of HLA-B in the Gut Microbiome

Recent studies have implicated the gut microbiome in the pathogenesis of AS. HLA-B27 transgenic rats develop spontaneous colitis and arthritis, and the severity of disease is influenced by the composition of the gut microbiota. The mechanism may involve the presentation of microbial peptides by B*27, leading to the activation of gut-homing T cells that cross-react with joint antigens. Alternatively, the misfolding of B*27 in gut epithelial cells may trigger the UPR and the production of IL-23, which drives Th17-mediated inflammation.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 HLA-B as a Pharmacogenomic Biomarker

HLA-B alleles are among the most clinically actionable pharmacogenomic biomarkers. The following alleles have FDA-approved label warnings or recommendations:

| Allele | Drug | Clinical Recommendation |
|--------|------|------------------------|
| HLA-B*57:01 | Abacavir | Contraindicated; screen before use |
| HLA-B*15:02 | Carbamazepine | Contraindicated in Asians; screen before use |
| HLA-B*15:02 | Phenytoin | Consider alternative in Asians |
| HLA-B*58:01 | Allopurinol | Contraindicated in Han Chinese and Thais |
| HLA-B*13:01 | Dapsone | Risk of dapsone hypersensitivity syndrome |

### 6.2 Therapeutic Targeting of HLA-B27 in AS

There are currently no small-molecule inhibitors that directly target HLA-B27. However, several therapeutic strategies indirectly modulate the pathogenic pathways initiated by B*27:

- **Anti-TNF-α biologics** (infliximab, adalimumab, etanercept, certolizumab, golimumab): Neutralize TNF-α, a key pro-inflammatory cytokine in AS. These agents are FDA-approved for AS and significantly reduce disease activity.
- **Anti-IL-17A biologics** (secukinumab, ixekizumab): Neutralize IL-17A, a cytokine produced by Th17 cells that is central to AS pathogenesis. Secukinumab and ixekizumab are FDA-approved for AS.
- **JAK inhibitors** (tofacitinib, upadacitinib): Inhibit Janus kinases, blocking the signaling of multiple cytokines (IL-6, IL-23, IFN-γ). Upadacitinib is FDA-approved for AS.
- **IL-23 inhibitors** (ustekinumab, guselkumab): Target IL-23, which is upstream of Th17 differentiation. However, clinical trials of ustekinumab in AS failed to meet primary endpoints, suggesting that IL-23 may not be the dominant driver in established disease.

### 6.3 Investigational Approaches Targeting HC-B27

The HC-B27 homodimer is an attractive therapeutic target because it is unique to B*27 and contributes to pathogenesis via KIR3DL2 engagement. Investigational approaches include:

- **Monoclonal antibodies** targeting HC-B27: A humanized antibody (HD6) that specifically recognizes HC-B27 homodimers has been developed and is in preclinical testing. The antibody blocks the interaction with KIR3DL2 and inhibits IL-17 production.
- **Small-molecule inhibitors of KIR3DL2**: Compounds that block the KIR3DL2-HC-B27 interaction are being screened. These would prevent the activation of Th17 cells and NK cells.
- **Peptide-based vaccines**: Vaccines that induce regulatory T cells specific for arthritogenic peptides are being explored as a tolerizing strategy.

### 6.4 Gene Therapy and Genome Editing

The CRISPR-Cas9 system has been used to knock out HLA-B in cell lines to study its function. In the context of AS, gene editing could theoretically be used to convert the AS-associated B*27:05 allele to a non-associated subtype (e.g., B*27:09) by introducing the Asp116His mutation. However, this approach is not clinically feasible due to the need for ex vivo editing and the risk of off-target effects.

### 6.5 Challenges in Targeting HLA-B

Targeting HLA-B is challenging because it is a ubiquitously expressed, non-redundant molecule essential for immune surveillance. Complete inhibition of HLA-B would result in severe immunodeficiency. Therefore, therapeutic strategies must be allele-specific and aim to modulate the pathogenic functions of B*27 (e.g., homodimer formation, arthritogenic peptide presentation) without compromising its protective functions (e.g., viral peptide presentation).

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession / ID | Description |
|----------|----------------|-------------|
| **HGNC** | HLA-B (ID: 4932) | Gene symbol and nomenclature |
| **NCBI Gene** | 3106 | Gene ID for HLA-B |
| **Ensembl** | ENSG00000234745 | Gene ID for HLA-B |
| **UniProt** | P01889 | Primary protein sequence and annotations |
| **RCSB PDB** | 1HOC | Crystal structure of B*27:05 with peptide |
| **PDB** | 3BP7 | Crystal structure of HC-B27 homodimer |
| **PDB** | 3UPR | Crystal structure of B*57:01 with abacavir |
| **IPD-IMGT/HLA** | HLA-B*27:05 | Allele-specific sequence and frequency |
| **ClinVar** | Various | Pathogenic variants and clinical significance |
| **dbSNP** | Various | Single nucleotide polymorphisms |
| **Gene Ontology (GO)** | GO:0002474 (antigen processing and presentation of peptide antigen via MHC class I); GO:0042605 (peptide antigen binding); GO:0005886 (plasma membrane) | Functional annotations |
| **STRING** | 9606.ENSP00000376261 | Protein-protein interaction network |
| **BioGRID** | 112233 | Physical and genetic interactions |
| **KEGG** | hsa04612 (Antigen processing and presentation) | Pathway annotation |
| **Reactome** | R-HSA-1236974 (Antigen processing-Cross presentation) | Pathway annotation |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. **Khan, M. A.** (2017). Ankylosing spondylitis and HLA-B27: A 50-year journey. *Journal of Rheumatology*, 44(6), 715–719. https://doi.org/10.3899/jrheum.170123

2. **Colbert, R. A., Tran, T. M., & Layh-Schmitt, G.** (2014). HLA-B27 misf